Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Socioeconomic disparities affect survival in malignant ovarian germ cell tumors in AYA population.

Bownes LV, Stafman LL, Maizlin II, Dellinger M, Gow KW, Goldin AB, Goldfarb M, Langer M, Raval MV, Doski JJ, Nuchtern JG, Vasudevan SA, Beierle EA.

J Surg Res. 2018 Feb;222:180-186.e3. doi: 10.1016/j.jss.2017.09.013. Epub 2017 Oct 6.

2.

Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009).

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD.

Gynecol Oncol. 2013 Nov;131(2):330-5. doi: 10.1016/j.ygyno.2013.08.028. Epub 2013 Aug 31.

PMID:
24001518
3.

Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010).

Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD.

Eur J Cancer. 2014 Jul;50(11):1942-50. doi: 10.1016/j.ejca.2014.03.288. Epub 2014 May 20.

PMID:
24857045
4.

Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis.

Lin KY, Bryant S, Miller DS, Kehoe SM, Richardson DL, Lea JS.

Gynecol Oncol. 2014 Jul;134(1):84-9. doi: 10.1016/j.ygyno.2014.05.003. Epub 2014 May 14.

PMID:
24836278
5.

Disparities in fertility-sparing surgery in adolescent and young women with stage I ovarian dysgerminoma.

Stafman LL, Maizlin II, Dellinger M, Gow KW, Goldfarb M, Nuchtern JG, Langer M, Vasudevan SA, Doski JJ, Goldin AB, Raval M, Beierle EA.

J Surg Res. 2018 Apr;224:38-43. doi: 10.1016/j.jss.2017.11.046. Epub 2017 Dec 22.

6.

Is Omentectomy Mandatory Among Early Stage (I, II) Malignant Ovarian Germ Cell Tumor Patients? A Retrospective Study of 223 Cases.

Xu W, Li Y.

Int J Gynecol Cancer. 2017 Sep;27(7):1373-1378. doi: 10.1097/IGC.0000000000001012.

PMID:
28520571
7.

[Clinical analysis of 15 cases of malignant ovarian germ cell tumors with lung metastasis].

Liu Y, Ren T, Feng FZ, Wan XR, Shen K, Xiang Y.

Zhonghua Fu Chan Ke Za Zhi. 2012 Jan;47(1):40-4. Chinese.

PMID:
22455692
8.

Racial disparities in survival in malignant germ cell tumors of the ovary.

Hinchcliff E, Rauh-Hain JA, Clemmer JT, Diver E, Hall T, Stall J, Growdon W, Clark R, Schorge J.

Gynecol Oncol. 2016 Mar;140(3):463-9. doi: 10.1016/j.ygyno.2016.01.006. Epub 2016 Jan 7.

PMID:
26773470
9.

Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group.

Billmire DF, Cullen JW, Rescorla FJ, Davis M, Schlatter MG, Olson TA, Malogolowkin MH, Pashankar F, Villaluna D, Krailo M, Egler RA, Rodriguez-Galindo C, Frazier AL.

J Clin Oncol. 2014 Feb 10;32(5):465-70. doi: 10.1200/JCO.2013.51.1006. Epub 2014 Jan 6.

10.

Racial disparities in survival among patients with germ cell tumors of the ovary--United States.

Bryant CS, Kumar S, Shah JP, Mahdi H, Ali-Fehmi R, Munkarah AR, Deppe G, Morris RT.

Gynecol Oncol. 2009 Sep;114(3):437-41. doi: 10.1016/j.ygyno.2009.05.039. Epub 2009 Jun 26.

PMID:
19560191
11.

Fertility-preserving surgery for advanced stage ovarian germ cell tumors.

Nasioudis D, Frey MK, Chapman-Davis E, Caputo TA, Holcomb K.

Gynecol Oncol. 2017 Dec;147(3):493-496. doi: 10.1016/j.ygyno.2017.10.010. Epub 2017 Oct 9.

PMID:
29021083
12.
13.

8-year analysis of the prevalence of lymph nodes metastasis, oncologic and pregnancy outcomes in apparent early-stage malignant ovarian germ cell tumors.

Chatchotikawong U, Ruengkhachorn I, Leelaphatanadit C, Phithakwatchara N.

Asian Pac J Cancer Prev. 2015;16(4):1609-13.

14.

Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis.

Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI.

Cancer. 2011 Sep 15;117(18):4277-85. doi: 10.1002/cncr.25969. Epub 2011 Mar 8.

15.

Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Bristow RE, Powell MA, Al-Hammadi N, Chen L, Miller JP, Roland PY, Mutch DG, Cliby WA.

J Natl Cancer Inst. 2013 Jun 5;105(11):823-32. doi: 10.1093/jnci/djt065. Epub 2013 Mar 28.

16.

Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.

Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S, Ferrandina G, Greggi S, Candiani M, Lorusso D.

Int J Gynecol Cancer. 2011 Nov;21(8):1414-21. doi: 10.1097/IGC.0b013e3182236582.

PMID:
21795985
17.

The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.

Mangili G, Sigismondi C, Lorusso D, Cormio G, Candiani M, Scarfone G, Mascilini F, Gadducci A, Mosconi AM, Scollo P, Cassani C, Pignata S, Ferrandina G.

Ann Oncol. 2017 Feb 1;28(2):333-338. doi: 10.1093/annonc/mdw563.

PMID:
27803008
18.

Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.

Long B, Chang J, Ziogas A, Tewari KS, Anton-Culver H, Bristow RE.

Am J Obstet Gynecol. 2015 Apr;212(4):468.e1-9. doi: 10.1016/j.ajog.2014.10.1104. Epub 2014 Oct 31.

19.

Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity.

Smith EC, Ziogas A, Anton-Culver H.

JAMA Surg. 2013 Jun;148(6):516-23. doi: 10.1001/jamasurg.2013.1680.

PMID:
23615681
20.

Small Numbers, Big Challenges: Adolescent and Young Adult Cancer Incidence and Survival in New Zealand.

Ballantine KR, Watson H, Macfarlane S, Winstanley M, Corbett RP, Spearing R, Stevanovic V, Yi M, Sullivan MJ.

J Adolesc Young Adult Oncol. 2017 Jun;6(2):277-285. doi: 10.1089/jayao.2016.0074. Epub 2017 Feb 16.

PMID:
28207291

Supplemental Content

Support Center